GROUNDBREAKING STUDY LAUNCHES

"Intermountain launches groundbreaking study using the PreTRM test to prevent preterm birth." Read more here

DOCTORS SPEAK OUT

"Women want good information. If a test predicts that they might have a preterm birth, they want to know."

PROTEOMIC INNOVATION

PreTRM Test Featured in Top-Tiered Scientific Journal as Example of Proteomic Test That Advances Patient Care. Read More

DOCTORS SPEAK OUT

"The value of the PreTRM test cannot be overestimated. We continue to deal with the vast majority of women who eventually go into preterm labor and deliver early with having absolutely no identifiable risk factors." Watch Dr. Shulman's video here

PROTEOMIC INNOVATION

“We developed a novel blood test to PREDICT, at an EARLY point in pregnancy, a woman’s individual risk of having a premature baby. We aim to achieve our vision of improving the health of newborns by enabling earlier, effective interventions that make a difference.” Dr. Greg Critchfield, CEO

DOCTORS SPEAK OUT

"With 1 in 10 women in the United States delivering prematurely, I believe every woman is an excellent candidate for the PreTRM test." Watch Dr. Mandel's video here

News

Intermountain Health and Christiana Care Health System Begin Enrollment on Two Landmark Preterm Birth Studies with PreTRM® Test

Salt Lake City, July 1, 2018 - Sera Prognostics®, The Pregnancy Company™, announces the recent launch of two new preterm birth studies using the PreTRM® test to identify high-risk mothers for intervention care. Read More >

Intermountain Healthcare Launches New Study to Determine Benefit of Proactive Interventions in Reducing Premature Births

May 29, 2018 - Intermountain Healthcare announced it is launching the first study of its kind that will use Sera's PreTRM® to identify those at risk for premature birth, and, in those with high risk, to evaluate the impact of early interventions designed to prolong their pregnancy and reduce the rate of premature delivery. Read More >

Key Strategies for Implementing Proteomics-Based Tests Across Disease States Highlighted in Current Opinion in Biotechnology

Seattle, WA and Salt Lake City, February 12 - Sera Prognostics, in collaboration with The Institute for Systems Biology and Integrated Diagnostics (Indi), today announced a paper entitled, "The building blocks of successful translation of proteomics to the clinic," by Leroy Hood and colleagues published online in Current Opinion in Biotechnology. Read More >

Awards

Our Goals

Providing An Individualized Risk Assessment to Predict and Manage premature birth, preeclampsia, and other Pregnancy Complications

Sera Prognostics is focused on improving maternal and infant health by developing simple blood tests to predict the risks of pregnancy complications. Our initial focus is on one of the most serious pregnancy complications—preterm birth—which affects 9.6% of pregnancies in the U.S. alone.

Early and accurate prediction of risk for pregnancy complications may help pregnant women and their doctors take action and make a difference by putting early interventions in place. Learn about the PreTRM® Test for Risk Management.